ABACUS, NCT05282953: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia |
|
|
| Recruiting | 1/2 | 12 | RoW | KIO-301 | Kiora Pharmaceuticals, Inc. | Retinitis Pigmentosa, Choroideremia | 12/24 | 01/25 | | |